And my friends goes, well, it's not on your website, so that means it's free, right
Marketing Merits Large diabetic population creating strong market demand Premium therapy enabling strong brand positioning Increasing acceptance among endocrinologists and diabetologists Expansion potential in obesity management Opportunity for awareness-based pharmaceutical marketing Marketing Demerits High therapy cost may limit affordability in price-sensitive markets Injectable therapy may reduce patient preference compared to oral medications Cold-chain storage and distribution requirements Growing competition from other GLP-1 receptor agonists Need for strong physician education and patient awareness programs Conclusion As India continues to face a growing burden of metabolic diseases, Semaglutide has the potential to reshape diabetes and obesity management while creating strong strategic opportunities in pharmaceutical marketing
In a subsequent study, lean Gipr AP-KO and Gipr AP-GFP mice were switched to an HFD on the same day as initiating 10 days of daily injections with either LIRA (or VEH) alone, or LIRA (or VEH) plus GIPR antagonist peptide (GIPR-antag) 6
Sheahan KH, Wahlberg EA, Gilbert MP (2020) An overview of GLP-1 agonists and recent cardiovascular outcomes trials
Before starting any GLP-1 medication, Service Members should work with their DoW medical officer or Primary Care Manager/Provider to ensure it is medically appropriate and to review how it might affect deployments, training, and overall readiness
